Relative levels of cytoprotection produced by analogs of choline and the role of α7-nicotinic acetylcholine receptors

Ramamohana R. Jonnala, John H. Graham, Alvin V. Terry, J. Warren Beach, Jennifer A. Young, Jerry J. Buccafusco

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Several analogs of the acetylcholine precursor molecule choline have been widely studied as potential false cholinergic neurotransmitters with the therapeutic goal of using them to limit cholinergic neurotransmission. More recently, choline itself has been shown to act as a full, if low potency, agonist at the α7 subtype of the nicotinic acetylcholine receptor. This pharmacological property has been associated with the ability of nicotine and other related α7 receptor agonists to offer neuroprotection in a variety of experimental models. We confirm here that choline offers a significant degree of protection against the cytotoxicity induced by growth factor deprivation in differentiated PC-12 cells. Choline-induced cytoprotection (∼1 mM) was about 3 orders of magnitude less potent than that for nicotine (EC50 = 0.7 μM). Choline also exhibited only about 40% of the full cytoprotective effect of nicotine. Ethyl substitution for choline's N-methyl groups did not result in a significant improvement over choline as a cytoprotective agent. In contrast, pyrrolidinecholine exhibited much greater potency (EC50 = 20 μM) and increased efficacy (about 55% of nicotine's effect) than choline. Like choline and nicotine, pyrrolidinecholine fully displaced [125I]α-bungarotoxin binding (Ki = 33 μM) and chronic exposure to the analog increased cell surface binding sites. The cytoprotective effects of the analog were completely inhibited by coincubation with methyllycaconitine (MLA), a selective α7-nicotinic receptor antagonist. These findings are consistent with the possibility that the choline structure may serve as a template for the development of novel agents with both α7-nicotinic agonist activity and potential neuroprotective ability, as many of these compounds, including pyrrolidinecholine, are transported along with choline into the central nervous system.

Original languageEnglish (US)
Pages (from-to)262-269
Number of pages8
JournalSynapse
Volume47
Issue number4
DOIs
StatePublished - Mar 15 2003

Fingerprint

Cytoprotection
Nicotinic Receptors
Choline
Nicotine
Cholinergic Agents
Nicotinic Agonists
Nicotinic Antagonists
Bungarotoxins
Synaptic Transmission
Acetylcholine
Neurotransmitter Agents
Intercellular Signaling Peptides and Proteins
Theoretical Models
Central Nervous System
Binding Sites
Pharmacology

Keywords

  • Cell culture
  • Cholinergic receptors
  • Growth factors
  • Neuroprotection
  • Upregulation

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Relative levels of cytoprotection produced by analogs of choline and the role of α7-nicotinic acetylcholine receptors. / Jonnala, Ramamohana R.; Graham, John H.; Terry, Alvin V.; Beach, J. Warren; Young, Jennifer A.; Buccafusco, Jerry J.

In: Synapse, Vol. 47, No. 4, 15.03.2003, p. 262-269.

Research output: Contribution to journalArticle

Jonnala, Ramamohana R. ; Graham, John H. ; Terry, Alvin V. ; Beach, J. Warren ; Young, Jennifer A. ; Buccafusco, Jerry J. / Relative levels of cytoprotection produced by analogs of choline and the role of α7-nicotinic acetylcholine receptors. In: Synapse. 2003 ; Vol. 47, No. 4. pp. 262-269.
@article{c5e6a5f15a1a444798ee3c12f77d7495,
title = "Relative levels of cytoprotection produced by analogs of choline and the role of α7-nicotinic acetylcholine receptors",
abstract = "Several analogs of the acetylcholine precursor molecule choline have been widely studied as potential false cholinergic neurotransmitters with the therapeutic goal of using them to limit cholinergic neurotransmission. More recently, choline itself has been shown to act as a full, if low potency, agonist at the α7 subtype of the nicotinic acetylcholine receptor. This pharmacological property has been associated with the ability of nicotine and other related α7 receptor agonists to offer neuroprotection in a variety of experimental models. We confirm here that choline offers a significant degree of protection against the cytotoxicity induced by growth factor deprivation in differentiated PC-12 cells. Choline-induced cytoprotection (∼1 mM) was about 3 orders of magnitude less potent than that for nicotine (EC50 = 0.7 μM). Choline also exhibited only about 40{\%} of the full cytoprotective effect of nicotine. Ethyl substitution for choline's N-methyl groups did not result in a significant improvement over choline as a cytoprotective agent. In contrast, pyrrolidinecholine exhibited much greater potency (EC50 = 20 μM) and increased efficacy (about 55{\%} of nicotine's effect) than choline. Like choline and nicotine, pyrrolidinecholine fully displaced [125I]α-bungarotoxin binding (Ki = 33 μM) and chronic exposure to the analog increased cell surface binding sites. The cytoprotective effects of the analog were completely inhibited by coincubation with methyllycaconitine (MLA), a selective α7-nicotinic receptor antagonist. These findings are consistent with the possibility that the choline structure may serve as a template for the development of novel agents with both α7-nicotinic agonist activity and potential neuroprotective ability, as many of these compounds, including pyrrolidinecholine, are transported along with choline into the central nervous system.",
keywords = "Cell culture, Cholinergic receptors, Growth factors, Neuroprotection, Upregulation",
author = "Jonnala, {Ramamohana R.} and Graham, {John H.} and Terry, {Alvin V.} and Beach, {J. Warren} and Young, {Jennifer A.} and Buccafusco, {Jerry J.}",
year = "2003",
month = "3",
day = "15",
doi = "10.1002/syn.10176",
language = "English (US)",
volume = "47",
pages = "262--269",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Relative levels of cytoprotection produced by analogs of choline and the role of α7-nicotinic acetylcholine receptors

AU - Jonnala, Ramamohana R.

AU - Graham, John H.

AU - Terry, Alvin V.

AU - Beach, J. Warren

AU - Young, Jennifer A.

AU - Buccafusco, Jerry J.

PY - 2003/3/15

Y1 - 2003/3/15

N2 - Several analogs of the acetylcholine precursor molecule choline have been widely studied as potential false cholinergic neurotransmitters with the therapeutic goal of using them to limit cholinergic neurotransmission. More recently, choline itself has been shown to act as a full, if low potency, agonist at the α7 subtype of the nicotinic acetylcholine receptor. This pharmacological property has been associated with the ability of nicotine and other related α7 receptor agonists to offer neuroprotection in a variety of experimental models. We confirm here that choline offers a significant degree of protection against the cytotoxicity induced by growth factor deprivation in differentiated PC-12 cells. Choline-induced cytoprotection (∼1 mM) was about 3 orders of magnitude less potent than that for nicotine (EC50 = 0.7 μM). Choline also exhibited only about 40% of the full cytoprotective effect of nicotine. Ethyl substitution for choline's N-methyl groups did not result in a significant improvement over choline as a cytoprotective agent. In contrast, pyrrolidinecholine exhibited much greater potency (EC50 = 20 μM) and increased efficacy (about 55% of nicotine's effect) than choline. Like choline and nicotine, pyrrolidinecholine fully displaced [125I]α-bungarotoxin binding (Ki = 33 μM) and chronic exposure to the analog increased cell surface binding sites. The cytoprotective effects of the analog were completely inhibited by coincubation with methyllycaconitine (MLA), a selective α7-nicotinic receptor antagonist. These findings are consistent with the possibility that the choline structure may serve as a template for the development of novel agents with both α7-nicotinic agonist activity and potential neuroprotective ability, as many of these compounds, including pyrrolidinecholine, are transported along with choline into the central nervous system.

AB - Several analogs of the acetylcholine precursor molecule choline have been widely studied as potential false cholinergic neurotransmitters with the therapeutic goal of using them to limit cholinergic neurotransmission. More recently, choline itself has been shown to act as a full, if low potency, agonist at the α7 subtype of the nicotinic acetylcholine receptor. This pharmacological property has been associated with the ability of nicotine and other related α7 receptor agonists to offer neuroprotection in a variety of experimental models. We confirm here that choline offers a significant degree of protection against the cytotoxicity induced by growth factor deprivation in differentiated PC-12 cells. Choline-induced cytoprotection (∼1 mM) was about 3 orders of magnitude less potent than that for nicotine (EC50 = 0.7 μM). Choline also exhibited only about 40% of the full cytoprotective effect of nicotine. Ethyl substitution for choline's N-methyl groups did not result in a significant improvement over choline as a cytoprotective agent. In contrast, pyrrolidinecholine exhibited much greater potency (EC50 = 20 μM) and increased efficacy (about 55% of nicotine's effect) than choline. Like choline and nicotine, pyrrolidinecholine fully displaced [125I]α-bungarotoxin binding (Ki = 33 μM) and chronic exposure to the analog increased cell surface binding sites. The cytoprotective effects of the analog were completely inhibited by coincubation with methyllycaconitine (MLA), a selective α7-nicotinic receptor antagonist. These findings are consistent with the possibility that the choline structure may serve as a template for the development of novel agents with both α7-nicotinic agonist activity and potential neuroprotective ability, as many of these compounds, including pyrrolidinecholine, are transported along with choline into the central nervous system.

KW - Cell culture

KW - Cholinergic receptors

KW - Growth factors

KW - Neuroprotection

KW - Upregulation

UR - http://www.scopus.com/inward/record.url?scp=0037444897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037444897&partnerID=8YFLogxK

U2 - 10.1002/syn.10176

DO - 10.1002/syn.10176

M3 - Article

C2 - 12539199

AN - SCOPUS:0037444897

VL - 47

SP - 262

EP - 269

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 4

ER -